摘要:
The invention concerns active substances modulating the expression of the receptors of the products of the POMC gene (MC-IR, MC-2R, and the μ opioid receptor), and possibly modulating the expression of POMC in cutaneous cells, notably to modulate the proliferation and differentiation of epidermal cells in order to re-epithelial, maintain innervation, irrigate the skin, or restore normal pigmentation, or to fight against aging, or to modulate pigmentation independently or not of cutaneous aging. The invention also concerns a method of screening such active substances.
摘要:
The invention concerns active substances modulating the expression of the receptors of the products of the POMC gene (MC-IR, MC-2R, and the μ opioid receptor), and possibly modulating the expression of POMC in cutaneous cells, notably to modulate the proliferation and differentiation of epidermal cells in order to re-epithelial, maintain innervation, irrigate the skin, or to fight against aging, or to modulate pigmentation independently or not of cutaneous aging. The invention also concerns a method of screening such active substances.
摘要:
The invention relates to the use of CD14+ monocytes for the production of dendritic cells. The invention comprises the use of CD14+ monocytes isolated from peripheral circulating blood for obtaining, by differentiation, at least one mixed population of Langerhans cells and interstitial dendritic cells, both Langerhans cells and interstitial dendritic cells being preconditioned and undifferentiated, and/or differentiated and immature, and/or mature, and/or interdigitated. The invention comprises their use in suspension, monolayer and three-dimensional cell and tissue models. The invention comprises the use of these cells and of these models as study models for the assessment of immunotoxicity/immunotolerance, for the development of cosmetic and pharmaceutical active principles and for the development and implementation of methods of cell and tissue therapy.
摘要:
The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.
摘要翻译:所公开的物质恢复LOX和NRAGE蛋白之间的正常共表达和相互作用。 特别地,有效量的调节SEQ ID NO:1的LOX的表达和/或活性的物质和/或调节SEQ ID NO:2的NRAGE的表达和/或活性的物质可用于制造 用于调节LOX和NRAGE蛋白之间相互作用的组合物,以调节增殖,分化和凋亡的细胞现象之间的平衡,特别是在这些现象之间的平衡受到干扰的情况下,特别是在LOX和 NRAGE不存在或改变。 本发明可以特别地治疗和/或预防皮肤老化,扁平苔藓,移植物抗宿主反应(GVH),湿疹,牛皮癣和癌症,特别是上皮癌,特别是基底细胞或脊髓细胞的皮肤上皮癌 类型。
摘要:
The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.
摘要翻译:所公开的物质恢复LOX和NRAGE蛋白之间的正常共表达和相互作用。 特别地,有效量的调节SEQ ID NO:1的LOX的表达和/或活性的物质和/或调节SEQ ID NO:2的NRAGE的表达和/或活性的物质可用于制造 用于调节LOX和NRAGE蛋白之间相互作用的组合物,以调节增殖,分化和凋亡的细胞现象之间的平衡,特别是在这些现象之间的平衡受到干扰的情况下,特别是在LOX和 NRAGE不存在或改变。 本发明可以特别地治疗和/或预防皮肤老化,扁平苔藓,移植物抗宿主反应(GVH),湿疹,牛皮癣和癌症,特别是上皮癌,特别是基底细胞或脊髓细胞的皮肤上皮癌 类型。
摘要:
The invention relates to a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins.The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of LOX of sequence ID no. 1, and/or that modulates the expression and/or activity of NRAGE of sequence ID no. 2, for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins in order to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered.The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer, of basocellular or spinocellular type.
摘要:
The present invention relates to a method for preparing Langerhans cells or interstitial dendritic cells or both from CD14+ monocytes stemming from the peripheral circulatory blood of a living being, wherein the method comprises differentiation of CD 14+ monocytes into either Langerhans cells, interstitial dendritic cells, or into both types of cells by placing the CD14+ monocytes in the presence of a cell environment comprising epithelial cells and/or mesenchymatous cells.The present invention also relates to cell or tissue models comprising such prepared Langerhans cells and/or interstitial dendritic cells, and optionally macrophages and endothelial cells, and to the uses of such cell or tissue models.
摘要:
The present invention relates to a method for preparing Langerhans cells or interstitial dendritic cells, or both, from CD14+ monocytes stemming from the peripheral circulatory blood of a living being, wherein the method comprises differentiation of CD14+ monocytes into either Langerhans cells, interstitial dendritic cells, or into both types of cells by placing the CD14+ monocytes in the presence of a cell environment comprising epithelial cells and/or mesenchymatous cells.The present invention also relates to cell or tissue models comprising such prepared Langerhans cells and/or interstitial dendritic cells, and optionally macrophages and endothelial cells, and to the uses of such cell or tissue models.
摘要:
The invention relates to substances which are capable of protecting FGF-2, to a composition for preventing or controlling degradation of FGF-2, and a method of protecting FGF-2 in the skin from degradation.In particular, the invention relates to an extract of Hibiscus Abelmoschus or ambrette, a rebokza extract, a gougizi berry extract, a banha extract, a lessonia extract, a mustard flour extract, a wooyin extract, a barley extract, and/or a sesame extract, in amounts effective to protect FGF-2 from its degradation.Further, the present invention allows the extracellular matrix to be restructured, particularly at the dermis, which is useful, for example, for controlling aging.
摘要:
The method for producing microparticles is characterized in that it comprises the following steps: preparation of an emulsion of a solution of a substance or a mixture of substances in a dispersing liquid wherein said substance or said mixture are substantially insoluble; incorporating to said dispersed phase a chemical agent substantially insoluble in the dispersing liquid so as to cause within the dispersed phase a chemical or physicochemical reaction responsible for the formation of microparticles which are then isolated.